about
Calcium channel blockers for primary Raynaud's phenomenonBSR and BHPR guideline for the treatment of systemic sclerosisHaemoglobinopathies and the rheumatologistDigital ulcers in systemic sclerosisCardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activityReduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrateDoes the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.Thermographic Abnormalities are Associated with Future Digital Ulcers and Death in Patients with Systemic Sclerosis.Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature.Coexistent digital gouty and infective flexor tenosynovitis.Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.Quantifying digital ulcers in systemic sclerosis: Reliability of digital planimetry in measuring lesion size.Digital ulcers in systemic sclerosis are associated with microangiopathic abnormalities of perilesional skin as assessed by capillaroscopy.A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia.A pilot study using high-frequency ultrasound to measure digital ulcers: a possible outcome measure in systemic sclerosis clinical trials?Anabolic androgenic steroid induced necrotising myopathy.A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders.Patients with systemic rheumatic diseases admitted to the intensive care unit: what the rheumatologist needs to know.Rheumatic Manifestations of HaemoglobinopathiesExploring the patient experience of digital ulcers in systemic sclerosisShould all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groupsInfected Calcinosis of the Knee in Limited Cutaneous Systemic Sclerosis: Figure 1Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosisLeft vocal cord paralysis in systemic lupus erythematosusSystemic sclerosisRaynaud's phenomenonResponse to 'Ultrasound characterization of cutaneous ulcers in systemic sclerosis'A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosisReliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial designPatient experiences of digital ulcer development and evolution in systemic sclerosisGender-related differences in systemic sclerosisRaynaud phenomenon and digital ulcers in systemic sclerosisA systematic review of internet-based information for individuals with Raynaud's phenomenon and patients with systemic sclerosisSignificant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseDrug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?Raynaud's phenomenonDigital ulcers secondary to radial artery thrombosis following arterial cannulation in systemic sclerosisPatient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report
P50
Q24186106-E59EBBF2-02AA-4C27-833C-8349414FDF05Q28068107-3280DB3F-28E4-4D25-AEBA-EE7FC4F868B7Q28075506-1D7199E8-E724-4931-986E-FBBE7B3EE8D2Q28080196-59F6E7CE-6233-4B45-9815-981292BA73BEQ28087636-CFE7625D-09E0-486C-B1A4-CFA74DA6537FQ36234054-18BA93AA-B85E-418F-BFBC-40CD52491EF9Q37222052-D71ECC9C-21A2-4090-88B1-3EE3BF9F7637Q38538817-9A2BA797-D866-4DE0-A0CC-BEF7266BE7CAQ38852487-1DE2104B-CC91-46FA-8E33-EA89ABB7FE3AQ38869385-597DA364-28F5-47EB-8C06-2BD77DDE8747Q38881229-5BF93A90-E5D3-40EF-9EB9-A6431CAC0004Q39031432-FA966952-9D3A-4BE6-9348-F5B8D7489FD4Q40187278-B2935C2F-D1CB-45FC-9418-8418A6A9695EQ40388574-80565B83-0B42-4E23-98D6-4BF67F736526Q40401167-355B83B0-8625-4222-91CF-0A3C1A7FE55AQ40477388-4498B374-F5E6-4A02-B86E-3661117B2C58Q44867354-EC8EDE54-FA4D-4573-9B9F-43BAD8C45AFCQ53167188-C40C39CF-98D3-4DB1-BF4F-130602813FD8Q54254407-90490287-61C4-499C-AFCC-0413780FA1DFQ57169413-4C143E9E-B609-422D-BD64-250B4E39385CQ57169866-47EE6099-0A47-4A03-8E77-1679DB8C7D97Q57178653-62364BAE-9E89-4DAA-97D0-4B9E55D043F9Q57473975-09F02510-7A62-4CD0-8779-D2A31ABD36C6Q61646501-3E3761D7-D99A-4FBC-8525-AE4C26D61AFAQ62228709-AD19AEB7-E917-49B9-A817-93CD4A33D4D3Q83875325-4498B2B3-BA2B-4984-B77C-F800008BEB6DQ85354558-A1E33500-BAC9-4EC4-A04D-4E7E55060AF2Q87913370-C592F884-158C-4A42-8846-1376EF581F16Q88380479-A1BF5E2A-2663-4990-B425-6DCDE734B126Q88969928-3DDC325E-AED2-4287-B885-E919C17530FCQ89016958-E27148CB-A422-4A4C-8B1A-8AA2636E72E0Q89591563-68EB15A3-81C0-4B0A-A5A7-7E4BCA8790C3Q89729488-DE51BAC0-B7B2-4B82-8F53-5C87C54DFA02Q89882906-E2CA29AD-2111-47D7-89DC-121E944824C3Q90173582-E1980C79-5306-4CEE-B620-59A9D8B6E7DFQ90659565-4B8092E3-C85D-43A1-A058-AD34AFDB6525Q91033387-58311721-CB69-4961-B488-3FDA658ACDC7Q91213734-59A991F1-4CAC-4A05-9C5F-13428E4927F2Q91226468-19BA094E-6770-4AF5-B995-AB047FDE6CC4Q91299070-60FB4139-215F-4089-80D7-22B1457830F1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Hughes
@ast
Michael Hughes
@en
Michael Hughes
@es
Michael Hughes
@sl
type
label
Michael Hughes
@ast
Michael Hughes
@en
Michael Hughes
@es
Michael Hughes
@sl
prefLabel
Michael Hughes
@ast
Michael Hughes
@en
Michael Hughes
@es
Michael Hughes
@sl
P106
P21
P31
P496
0000-0003-3361-4909